BCL2 and breast cancer: Indirect evidence that targeting of Mcl-1 in combination with lapitinib could sensitize breast cancer cells to radiotherapies was gained using the pan-BCL2 inhibitor obatoclax, a BH3-mimetic that displaces BIM from all anti-apoptotic BCL2 family members.